My 4-Min Measure Towards OPHN1

We computed corresponding standard errors in a similar way. We included the STAR trial only for the raloxifene effects, and results for the overall effect do not include data from that trial. We explored random-effects models, which CCI779 account for variability between trials, and assessed trial heterogeneity with Q statistics and I2 estimates. 22 Data are plotted as the proportion of women with the event as a function of follow-up time with Kaplan-Meier methods. 23 To compare outcomes between tamoxifen and raloxifene we computed the ratio of HRs for comparisons of each drug with placebo, then added the direct comparison from the STAR trial as a separate stratum to obtain a summary hazard ratio. For analysis we used STATA (version 11.2) with the meta command. Results are presented as HRs with 95% CIs and two-sided p-values. Neither Cancer Research UK nor the funding sources for the individual studies had a role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author and IS had full access to all the data in the study, and all authors had access to analyses. All authors read and approved the final decision to submit OPHN1 for publication. We included nine trials with 83?399 participants find more and 306?617 women-years of follow-up (table 1). Median follow-up was 65 months (IQR 54�C93). Figure 1 shows Kaplan-Meier curves for all breast cancers and invasive ER-positive breast cancer for all trials except the STAR trial. Annual rates of breast cancer incidence varied substantially between trials (table 2), probably because of different entry criteria. The overall reduction in all breast cancer (including ductal carcinoma in situ) was 38% (p